NO320805B1 - Substituerte bisykliske heterosykler, fremgangsmate for deres fremstilling,anvendelse for fremstilling av antifedme- og hypokolesterolemiske midler og farmasoytiske sammensetninger som inneholder dem. - Google Patents
Substituerte bisykliske heterosykler, fremgangsmate for deres fremstilling,anvendelse for fremstilling av antifedme- og hypokolesterolemiske midler og farmasoytiske sammensetninger som inneholder dem. Download PDFInfo
- Publication number
- NO320805B1 NO320805B1 NO20015259A NO20015259A NO320805B1 NO 320805 B1 NO320805 B1 NO 320805B1 NO 20015259 A NO20015259 A NO 20015259A NO 20015259 A NO20015259 A NO 20015259A NO 320805 B1 NO320805 B1 NO 320805B1
- Authority
- NO
- Norway
- Prior art keywords
- phenyl
- dihydro
- ethoxy
- substituted
- guanidine
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 14
- 239000008194 pharmaceutical composition Substances 0.000 title claims 5
- 230000003579 anti-obesity Effects 0.000 title 1
- 239000000883 anti-obesity agent Substances 0.000 title 1
- 239000003529 anticholesteremic agent Substances 0.000 title 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 title 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims 183
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 179
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims 122
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 122
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 122
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 claims 122
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims 122
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims 122
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 claims 122
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 claims 122
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims 122
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 120
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 120
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims 120
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims 120
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims 117
- -1 Ethyl-(E)-3-[2-(2,3-dimethyl-1,4-benzoxazin-4-yl)methylbenzofuran-5-yl]-2-ethoxy-propenoate Chemical compound 0.000 claims 105
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 78
- 150000001875 compounds Chemical class 0.000 claims 75
- 150000003839 salts Chemical class 0.000 claims 72
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 65
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 63
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 63
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims 62
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 61
- HMBHAQMOBKLWRX-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxine-3-carboxylic acid Chemical compound C1=CC=C2OC(C(=O)O)COC2=C1 HMBHAQMOBKLWRX-UHFFFAOYSA-N 0.000 claims 61
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims 61
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical class [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 61
- 239000004475 Arginine Substances 0.000 claims 61
- QMXOFBXZEKTJIK-UHFFFAOYSA-N Glycinol Natural products C1=C(O)C=C2OCC3(O)C4=CC=C(O)C=C4OC3C2=C1 QMXOFBXZEKTJIK-UHFFFAOYSA-N 0.000 claims 61
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims 61
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims 61
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 61
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 61
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 61
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 61
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 61
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims 61
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 61
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 61
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims 61
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 61
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 61
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 61
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 61
- 239000004472 Lysine Substances 0.000 claims 61
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 claims 61
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 61
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 61
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 claims 61
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 61
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 61
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims 61
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 61
- 239000004473 Threonine Substances 0.000 claims 61
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 61
- 235000004279 alanine Nutrition 0.000 claims 61
- 150000003863 ammonium salts Chemical class 0.000 claims 61
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 61
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 claims 61
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims 61
- 229960003237 betaine Drugs 0.000 claims 61
- 229960001948 caffeine Drugs 0.000 claims 61
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims 61
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims 61
- 229960001231 choline Drugs 0.000 claims 61
- 229940075419 choline hydroxide Drugs 0.000 claims 61
- 229910052802 copper Inorganic materials 0.000 claims 61
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 61
- 235000018417 cysteine Nutrition 0.000 claims 61
- 229960003067 cystine Drugs 0.000 claims 61
- 125000005265 dialkylamine group Chemical group 0.000 claims 61
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims 61
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims 61
- 229960002442 glucosamine Drugs 0.000 claims 61
- 150000002357 guanidines Chemical class 0.000 claims 61
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 61
- 229960002591 hydroxyproline Drugs 0.000 claims 61
- 229910052742 iron Inorganic materials 0.000 claims 61
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 claims 61
- 229910052749 magnesium Inorganic materials 0.000 claims 61
- 229910052748 manganese Inorganic materials 0.000 claims 61
- 229960003104 ornithine Drugs 0.000 claims 61
- 150000003212 purines Chemical class 0.000 claims 61
- 229940063673 spermidine Drugs 0.000 claims 61
- 229960004559 theobromine Drugs 0.000 claims 61
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims 61
- 235000019157 thiamine Nutrition 0.000 claims 61
- 229960003495 thiamine Drugs 0.000 claims 61
- 239000011721 thiamine Substances 0.000 claims 61
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims 61
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 claims 61
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 61
- 239000004474 valine Substances 0.000 claims 61
- 229910052725 zinc Inorganic materials 0.000 claims 61
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 claims 60
- 229940013085 2-diethylaminoethanol Drugs 0.000 claims 60
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 claims 60
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 claims 60
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims 60
- 239000004471 Glycine Substances 0.000 claims 60
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 60
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims 60
- 150000003927 aminopyridines Chemical class 0.000 claims 60
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 claims 60
- 229960003194 meglumine Drugs 0.000 claims 60
- 229930182817 methionine Natural products 0.000 claims 60
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims 60
- 229960004919 procaine Drugs 0.000 claims 60
- 125000005270 trialkylamine group Chemical group 0.000 claims 60
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 60
- 229960000281 trometamol Drugs 0.000 claims 60
- MWGATWIBSKHFMR-UHFFFAOYSA-N 2-anilinoethanol Chemical compound OCCNC1=CC=CC=C1 MWGATWIBSKHFMR-UHFFFAOYSA-N 0.000 claims 59
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 59
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 59
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 claims 59
- 229940043237 diethanolamine Drugs 0.000 claims 59
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 59
- 229960000310 isoleucine Drugs 0.000 claims 59
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 59
- 229940012017 ethylenediamine Drugs 0.000 claims 58
- 150000005005 aminopyrimidines Chemical class 0.000 claims 54
- 229910052739 hydrogen Inorganic materials 0.000 claims 54
- 239000001257 hydrogen Substances 0.000 claims 53
- 229910052757 nitrogen Inorganic materials 0.000 claims 52
- 150000002431 hydrogen Chemical class 0.000 claims 49
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 claims 42
- NOUUUQMKVOUUNR-UHFFFAOYSA-N n,n'-diphenylethane-1,2-diamine Chemical compound C=1C=CC=CC=1NCCNC1=CC=CC=C1 NOUUUQMKVOUUNR-UHFFFAOYSA-N 0.000 claims 32
- WNYIBZHOMJZDKN-UHFFFAOYSA-N n-(2-acetamidoethyl)acetamide Chemical compound CC(=O)NCCNC(C)=O WNYIBZHOMJZDKN-UHFFFAOYSA-N 0.000 claims 32
- 229910052799 carbon Inorganic materials 0.000 claims 30
- 150000001721 carbon Chemical group 0.000 claims 28
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 22
- 125000003118 aryl group Chemical group 0.000 claims 20
- 125000000623 heterocyclic group Chemical group 0.000 claims 19
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 19
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 18
- 125000001624 naphthyl group Chemical group 0.000 claims 18
- 229910052760 oxygen Inorganic materials 0.000 claims 18
- 239000001301 oxygen Substances 0.000 claims 18
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 16
- 125000000217 alkyl group Chemical group 0.000 claims 14
- PADPKJACPLYMPK-UHFFFAOYSA-N n',n'-diphenylethane-1,2-diamine Chemical compound C=1C=CC=CC=1N(CCN)C1=CC=CC=C1 PADPKJACPLYMPK-UHFFFAOYSA-N 0.000 claims 14
- 125000003710 aryl alkyl group Chemical group 0.000 claims 12
- 239000002253 acid Substances 0.000 claims 11
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 claims 11
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 10
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 10
- 125000005842 heteroatom Chemical group 0.000 claims 10
- 125000004043 oxo group Chemical group O=* 0.000 claims 10
- 229910052717 sulfur Chemical group 0.000 claims 10
- 239000011593 sulfur Chemical group 0.000 claims 10
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 9
- 125000001072 heteroaryl group Chemical group 0.000 claims 9
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical group 0.000 claims 8
- 125000002252 acyl group Chemical group 0.000 claims 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 7
- 239000000243 solution Substances 0.000 claims 7
- 239000012453 solvate Substances 0.000 claims 7
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 6
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims 6
- HDSBTCWAQRSPFI-UHFFFAOYSA-N 2-ethoxy-3-[4-[2-(3-oxo-1,4-benzoxazin-4-yl)ethoxy]phenyl]propanoic acid Chemical compound C1=CC(CC(OCC)C(O)=O)=CC=C1OCCN1C2=CC=CC=C2OCC1=O HDSBTCWAQRSPFI-UHFFFAOYSA-N 0.000 claims 5
- YPCXMZHWVUITBA-UHFFFAOYSA-N 3-[4-[2-(2,3-dihydro-1,4-benzothiazin-4-yl)ethoxy]phenyl]-2-phenoxypropanoic acid Chemical compound C=1C=C(OCCN2C3=CC=CC=C3SCC2)C=CC=1CC(C(=O)O)OC1=CC=CC=C1 YPCXMZHWVUITBA-UHFFFAOYSA-N 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- HBDHWQKZINLCPK-UHFFFAOYSA-N 2-ethoxy-3-[4-[2-(3-oxo-1,4-benzothiazin-4-yl)ethoxy]phenyl]propanoic acid Chemical compound C1=CC(CC(OCC)C(O)=O)=CC=C1OCCN1C2=CC=CC=C2SCC1=O HBDHWQKZINLCPK-UHFFFAOYSA-N 0.000 claims 4
- ODYZDBJNDOGJKT-UHFFFAOYSA-N 3-[4-[2-(2,3-dihydro-1,4-benzothiazin-4-yl)ethoxy]phenyl]-2-methyl-2-phenoxypropanoic acid Chemical compound C=1C=C(OCCN2C3=CC=CC=C3SCC2)C=CC=1CC(C)(C(O)=O)OC1=CC=CC=C1 ODYZDBJNDOGJKT-UHFFFAOYSA-N 0.000 claims 4
- GGAOXTIHFIYDPC-UHFFFAOYSA-N 3-[4-[2-(2,3-dihydro-1,4-benzoxazin-4-yl)ethoxy]phenyl]-2-ethoxypropanoic acid Chemical compound C1=CC(CC(OCC)C(O)=O)=CC=C1OCCN1C2=CC=CC=C2OCC1 GGAOXTIHFIYDPC-UHFFFAOYSA-N 0.000 claims 4
- UVYZEYXMOFYLQT-UHFFFAOYSA-N 3-[4-[2-(2,3-dihydro-1,4-benzoxazin-4-yl)ethoxy]phenyl]-2-hydroxypropanoic acid Chemical compound C1=CC(CC(O)C(O)=O)=CC=C1OCCN1C2=CC=CC=C2OCC1 UVYZEYXMOFYLQT-UHFFFAOYSA-N 0.000 claims 4
- KRNNZPFAPLHPNP-UHFFFAOYSA-N 3-[4-[2-(2,3-dihydro-1,4-benzoxazin-4-yl)ethoxy]phenyl]-2-phenoxypropanoic acid Chemical compound C=1C=C(OCCN2C3=CC=CC=C3OCC2)C=CC=1CC(C(=O)O)OC1=CC=CC=C1 KRNNZPFAPLHPNP-UHFFFAOYSA-N 0.000 claims 4
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 4
- 125000005100 aryl amino carbonyl group Chemical group 0.000 claims 4
- HMSINBTULZNZRC-UHFFFAOYSA-N n-acetyl-n-(2-aminoethyl)acetamide Chemical compound CC(=O)N(C(C)=O)CCN HMSINBTULZNZRC-UHFFFAOYSA-N 0.000 claims 4
- XBHQOMRKOUANQQ-UHFFFAOYSA-N 2-ethoxypropanoic acid Chemical compound CCOC(C)C(O)=O XBHQOMRKOUANQQ-UHFFFAOYSA-N 0.000 claims 3
- XTADJISLWFZGIO-UHFFFAOYSA-N 3-[4-[(4-benzyl-2,3-dihydro-1,4-benzoxazin-2-yl)methoxy]phenyl]-2-ethoxypropanoic acid Chemical compound C1=CC(CC(OCC)C(O)=O)=CC=C1OCC1OC2=CC=CC=C2N(CC=2C=CC=CC=2)C1 XTADJISLWFZGIO-UHFFFAOYSA-N 0.000 claims 3
- GKBWKSJWXJMEEQ-UHFFFAOYSA-N 3-[4-[2-(2,3-dihydro-1,4-benzothiazin-4-yl)ethoxy]phenyl]-2-ethoxypropanoic acid Chemical compound C1=CC(CC(OCC)C(O)=O)=CC=C1OCCN1C2=CC=CC=C2SCC1 GKBWKSJWXJMEEQ-UHFFFAOYSA-N 0.000 claims 3
- NPIGSANZDQELNH-UHFFFAOYSA-N 3-[4-[2-(2,3-dihydro-1,4-benzoxazin-4-yl)ethoxy]phenyl]-2-ethoxy-2-methylpropanoic acid Chemical compound C1=CC(CC(C)(OCC)C(O)=O)=CC=C1OCCN1C2=CC=CC=C2OCC1 NPIGSANZDQELNH-UHFFFAOYSA-N 0.000 claims 3
- LVGVAOOYUUFWNS-UHFFFAOYSA-N 3-[4-[2-(2,3-dihydro-1,4-benzoxazin-4-yl)ethoxy]phenyl]-2-phenylmethoxypropanoic acid Chemical class C=1C=C(OCCN2C3=CC=CC=C3OCC2)C=CC=1CC(C(=O)O)OCC1=CC=CC=C1 LVGVAOOYUUFWNS-UHFFFAOYSA-N 0.000 claims 3
- BAOZZIMJVLTJIQ-UHFFFAOYSA-N 3-[6-[2-(2,3-dihydro-1,4-benzothiazin-4-yl)ethoxy]naphthalen-1-yl]-2-ethoxypropanoic acid Chemical class C1CSC2=CC=CC=C2N1CCOC1=CC=C2C(CC(OCC)C(O)=O)=CC=CC2=C1 BAOZZIMJVLTJIQ-UHFFFAOYSA-N 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 150000001408 amides Chemical class 0.000 claims 3
- 150000001412 amines Chemical class 0.000 claims 3
- PQXCSWWRPIMVIP-UHFFFAOYSA-N ethyl 3-[4-[2-(2,3-dihydro-1,4-benzoxazin-4-yl)ethoxy]phenyl]-2-hexoxypropanoate Chemical compound C1=CC(CC(OCCCCCC)C(=O)OCC)=CC=C1OCCN1C2=CC=CC=C2OCC1 PQXCSWWRPIMVIP-UHFFFAOYSA-N 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 3
- UNILYMLSNCMOMF-UHFFFAOYSA-N methyl 3-[4-[2-(2,3-dihydro-1,4-benzoxazin-4-yl)ethoxy]phenyl]-2-phenoxypropanoate Chemical compound C=1C=C(OCCN2C3=CC=CC=C3OCC2)C=CC=1CC(C(=O)OC)OC1=CC=CC=C1 UNILYMLSNCMOMF-UHFFFAOYSA-N 0.000 claims 3
- MHMMGRGOOBJCSR-UHFFFAOYSA-N 2-[[4-[2-(2,3-dihydro-1,4-benzoxazin-4-yl)ethoxy]phenyl]methyl]-2-ethoxy-3-(2-fluorophenyl)propanoic acid Chemical class C=1C=C(OCCN2C3=CC=CC=C3OCC2)C=CC=1CC(OCC)(C(O)=O)CC1=CC=CC=C1F MHMMGRGOOBJCSR-UHFFFAOYSA-N 0.000 claims 2
- RJRKOQPJMZOZAQ-UHFFFAOYSA-N 2-butoxy-3-[4-[2-(2,3-dihydro-1,4-benzoxazin-4-yl)ethoxy]phenyl]propanoic acid Chemical class C1=CC(CC(OCCCC)C(O)=O)=CC=C1OCCN1C2=CC=CC=C2OCC1 RJRKOQPJMZOZAQ-UHFFFAOYSA-N 0.000 claims 2
- VUMWEERYGJRFPZ-UHFFFAOYSA-N 3-[2-(2,3-dihydro-1,4-benzothiazin-4-ylmethyl)-1-benzofuran-5-yl]-2-ethoxypropanoic acid Chemical class C1CSC2=CC=CC=C2N1CC1=CC2=CC(CC(OCC)C(O)=O)=CC=C2O1 VUMWEERYGJRFPZ-UHFFFAOYSA-N 0.000 claims 2
- FJDMCJKQTKAEJG-UHFFFAOYSA-N 3-[2-(2,3-dihydro-1,4-benzoxazin-4-ylmethyl)-1-benzofuran-5-yl]-2-ethoxypropanoic acid Chemical class C1COC2=CC=CC=C2N1CC1=CC2=CC(CC(OCC)C(O)=O)=CC=C2O1 FJDMCJKQTKAEJG-UHFFFAOYSA-N 0.000 claims 2
- DQDCKBWSBKGOQH-UHFFFAOYSA-N 3-[4-[2-(2,3-dihydro-1,4-benzothiazin-4-yl)ethoxy]phenyl]-2-ethoxypropanamide Chemical compound C1=CC(CC(OCC)C(N)=O)=CC=C1OCCN1C2=CC=CC=C2SCC1 DQDCKBWSBKGOQH-UHFFFAOYSA-N 0.000 claims 2
- KCOTUBYAAREJGC-UHFFFAOYSA-N 3-[4-[2-(2,3-dihydro-1,4-benzoxazin-4-yl)ethoxy]phenyl]-2-methyl-2-phenoxypropanoic acid Chemical class C=1C=C(OCCN2C3=CC=CC=C3OCC2)C=CC=1CC(C)(C(O)=O)OC1=CC=CC=C1 KCOTUBYAAREJGC-UHFFFAOYSA-N 0.000 claims 2
- 239000005711 Benzoic acid Substances 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 2
- 206010036049 Polycystic ovaries Diseases 0.000 claims 2
- 125000004423 acyloxy group Chemical group 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- CMKWTHLWQUZXOB-UHFFFAOYSA-N methyl 3-[4-[2-(2,3-dihydro-1,4-benzothiazin-4-yl)ethoxy]phenyl]-2-methyl-2-phenoxypropanoate Chemical compound C=1C=C(OCCN2C3=CC=CC=C3SCC2)C=CC=1CC(C)(C(=O)OC)OC1=CC=CC=C1 CMKWTHLWQUZXOB-UHFFFAOYSA-N 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- ROHGIKOWUPXUPJ-UHFFFAOYSA-N 3-[4-[(4-benzyl-2,3-dihydro-1,4-benzoxazin-2-yl)methoxy]phenyl]-2-ethoxy-2-(4-nitrophenyl)propanoic acid Chemical compound C=1C=C([N+]([O-])=O)C=CC=1C(OCC)(C(O)=O)CC(C=C1)=CC=C1OCC(OC1=CC=CC=C11)CN1CC1=CC=CC=C1 ROHGIKOWUPXUPJ-UHFFFAOYSA-N 0.000 claims 1
- XSSLBZJZTWIQPZ-UHFFFAOYSA-N 3-[4-[2-(2,3-dihydro-1,4-benzothiazin-4-yl)ethoxy]phenyl]-2-hydroxypropanoic acid Chemical class C1=CC(CC(O)C(O)=O)=CC=C1OCCN1C2=CC=CC=C2SCC1 XSSLBZJZTWIQPZ-UHFFFAOYSA-N 0.000 claims 1
- BSDNCIHDROVWCO-UHFFFAOYSA-N 3-[4-[2-(2,3-dihydro-1,4-benzoxazin-4-yl)ethoxy]phenyl]-2-ethoxy-n-methylpropanamide Chemical compound C1=CC(CC(OCC)C(=O)NC)=CC=C1OCCN1C2=CC=CC=C2OCC1 BSDNCIHDROVWCO-UHFFFAOYSA-N 0.000 claims 1
- BFLZHLOGOOYEAN-UHFFFAOYSA-N 3-[4-[2-(2,3-dihydro-1,4-benzoxazin-4-yl)ethoxy]phenyl]-2-hexoxypropanoic acid Chemical class C1=CC(CC(OCCCCCC)C(O)=O)=CC=C1OCCN1C2=CC=CC=C2OCC1 BFLZHLOGOOYEAN-UHFFFAOYSA-N 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 229920001268 Cholestyramine Polymers 0.000 claims 1
- 229920002911 Colestipol Polymers 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000002249 Diabetes Complications Diseases 0.000 claims 1
- 206010012655 Diabetic complications Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims 1
- 102000016267 Leptin Human genes 0.000 claims 1
- 108010092277 Leptin Proteins 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 206010068871 Myotonic dystrophy Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 241001130469 Tila Species 0.000 claims 1
- 206010048214 Xanthoma Diseases 0.000 claims 1
- 206010048215 Xanthomatosis Diseases 0.000 claims 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 claims 1
- 125000004442 acylamino group Chemical group 0.000 claims 1
- 239000003288 aldose reductase inhibitor Substances 0.000 claims 1
- 229940090865 aldose reductase inhibitors used in diabetes Drugs 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 150000008064 anhydrides Chemical group 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 125000001691 aryl alkyl amino group Chemical group 0.000 claims 1
- 125000001769 aryl amino group Chemical group 0.000 claims 1
- 229960001541 benzthiazide Drugs 0.000 claims 1
- JIXMKUHFRDTJOR-VEILYXNESA-N c1cc(/C=C(\OCC)C(=O)OCC)ccc1OCC1CN(Cc2ccccc2)c2ccccc2O1 Chemical compound c1cc(/C=C(\OCC)C(=O)OCC)ccc1OCC1CN(Cc2ccccc2)c2ccccc2O1 JIXMKUHFRDTJOR-VEILYXNESA-N 0.000 claims 1
- FOGZPJPPKVOAEG-LKUDQCMESA-N c1cc(OCCN2CCSc3ccccc32)ccc1\C=C(C(=O)OCC)\Oc1ccccc1 Chemical compound c1cc(OCCN2CCSc3ccccc32)ccc1\C=C(C(=O)OCC)\Oc1ccccc1 FOGZPJPPKVOAEG-LKUDQCMESA-N 0.000 claims 1
- TUVOUXLADZJVBL-RCCKNPSSSA-N c1cc(\C=C(\OCC)C(=O)OCC)ccc1OCCN1C(=O)COc2ccccc12 Chemical compound c1cc(\C=C(\OCC)C(=O)OCC)ccc1OCCN1C(=O)COc2ccccc12 TUVOUXLADZJVBL-RCCKNPSSSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 230000020411 cell activation Effects 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000003920 cognitive function Effects 0.000 claims 1
- GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 claims 1
- 229960002604 colestipol Drugs 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 230000018044 dehydration Effects 0.000 claims 1
- 238000006297 dehydration reaction Methods 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 238000005906 dihydroxylation reaction Methods 0.000 claims 1
- 210000002889 endothelial cell Anatomy 0.000 claims 1
- FDBUMAZMKYPOHP-LHLOQNFPSA-N ethyl (E)-3-[4-[2-(2,3-dihydro-1,4-benzoxazin-4-yl)ethoxy]phenyl]-2-phenoxyprop-2-enoate Chemical compound C=1C=C(OCCN2C3=CC=CC=C3OCC2)C=CC=1\C=C(C(=O)OCC)\OC1=CC=CC=C1 FDBUMAZMKYPOHP-LHLOQNFPSA-N 0.000 claims 1
- ATTHDPUAOALIJO-PLRJNAJWSA-N ethyl (Z)-3-[6-[2-(2,3-dihydro-1,4-benzothiazin-4-yl)ethoxy]naphthalen-1-yl]-2-ethoxyprop-2-enoate Chemical compound C1CSC2=CC=CC=C2N1CCOC1=CC=C2C(/C=C(\OCC)C(=O)OCC)=CC=CC2=C1 ATTHDPUAOALIJO-PLRJNAJWSA-N 0.000 claims 1
- CBJLDOAEMVGSDO-UCQKPKSFSA-N ethyl (z)-3-[2-(2,3-dihydro-1,4-benzoxazin-4-ylmethyl)-1-benzofuran-5-yl]-2-ethoxyprop-2-enoate Chemical compound C1COC2=CC=CC=C2N1CC1=CC2=CC(/C=C(\OCC)C(=O)OCC)=CC=C2O1 CBJLDOAEMVGSDO-UCQKPKSFSA-N 0.000 claims 1
- CKYQFZCHIWADPF-UHFFFAOYSA-N ethyl 2-butoxy-3-[4-[2-(2,3-dihydro-1,4-benzoxazin-4-yl)ethoxy]phenyl]propanoate Chemical compound C1=CC(CC(OCCCC)C(=O)OCC)=CC=C1OCCN1C2=CC=CC=C2OCC1 CKYQFZCHIWADPF-UHFFFAOYSA-N 0.000 claims 1
- 229940093470 ethylene Drugs 0.000 claims 1
- 229940125753 fibrate Drugs 0.000 claims 1
- 206010061989 glomerulosclerosis Diseases 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 230000001631 hypertensive effect Effects 0.000 claims 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 1
- 229940039781 leptin Drugs 0.000 claims 1
- ZOVHBEKKCBZCRQ-UHFFFAOYSA-N methyl 2-ethoxy-3-[4-[(4-methyl-2,3-dihydro-1,4-benzoxazin-2-yl)methoxy]phenyl]propanoate Chemical compound C1=CC(CC(OCC)C(=O)OC)=CC=C1OCC1OC2=CC=CC=C2N(C)C1 ZOVHBEKKCBZCRQ-UHFFFAOYSA-N 0.000 claims 1
- QYYNQSDAZIANQL-UHFFFAOYSA-N methyl 2-ethoxy-3-[4-[2-(3-oxo-1,4-benzoxazin-4-yl)ethoxy]phenyl]propanoate Chemical compound C1=CC(CC(OCC)C(=O)OC)=CC=C1OCCN1C2=CC=CC=C2OCC1=O QYYNQSDAZIANQL-UHFFFAOYSA-N 0.000 claims 1
- FHJUQGWOIOSEHW-UHFFFAOYSA-N methyl 3-[4-[2-(2,3-dihydro-1,4-benzothiazin-4-yl)ethoxy]phenyl]-2-ethoxypropanoate Chemical compound C1=CC(CC(OCC)C(=O)OC)=CC=C1OCCN1C2=CC=CC=C2SCC1 FHJUQGWOIOSEHW-UHFFFAOYSA-N 0.000 claims 1
- XFECTTWJODDBNV-UHFFFAOYSA-N methyl 3-[4-[2-(2,3-dihydro-1,4-benzoxazin-4-yl)ethoxy]phenyl]-2-ethoxypropanoate Chemical compound C1=CC(CC(OCC)C(=O)OC)=CC=C1OCCN1C2=CC=CC=C2OCC1 XFECTTWJODDBNV-UHFFFAOYSA-N 0.000 claims 1
- PBZSAMQPGQTMLD-UHFFFAOYSA-N methyl 3-[6-[2-(2,3-dihydro-1,4-benzothiazin-4-yl)ethoxy]naphthalen-1-yl]-2-ethoxypropanoate Chemical compound C1CSC2=CC=CC=C2N1CCOC1=CC=C2C(CC(OCC)C(=O)OC)=CC=CC2=C1 PBZSAMQPGQTMLD-UHFFFAOYSA-N 0.000 claims 1
- GGPUBHNWQRASQZ-UHFFFAOYSA-N n-benzyl-3-[4-[2-(2,3-dihydro-1,4-benzothiazin-4-yl)ethoxy]phenyl]-2-ethoxypropanamide Chemical compound C=1C=C(OCCN2C3=CC=CC=C3SCC2)C=CC=1CC(OCC)C(=O)NCC1=CC=CC=C1 GGPUBHNWQRASQZ-UHFFFAOYSA-N 0.000 claims 1
- 201000009925 nephrosclerosis Diseases 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 238000002203 pretreatment Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 claims 1
- 229960003912 probucol Drugs 0.000 claims 1
- ZIKJCAPMXXTMDD-UHFFFAOYSA-M sodium;2-(1-hydroxycyclohexyl)butanoate Chemical class [Na+].CCC(C([O-])=O)C1(O)CCCCC1 ZIKJCAPMXXTMDD-UHFFFAOYSA-M 0.000 claims 1
- 150000003458 sulfonic acid derivatives Chemical class 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 125000004665 trialkylsilyl group Chemical group 0.000 claims 1
- 210000002268 wool Anatomy 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN484MA1999 | 1999-04-28 | ||
PCT/IB2000/000501 WO2000066572A1 (en) | 1999-04-28 | 2000-04-25 | Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20015259D0 NO20015259D0 (no) | 2001-10-26 |
NO20015259L NO20015259L (no) | 2001-11-15 |
NO320805B1 true NO320805B1 (no) | 2006-01-30 |
Family
ID=11095336
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20015259A NO320805B1 (no) | 1999-04-28 | 2001-10-26 | Substituerte bisykliske heterosykler, fremgangsmate for deres fremstilling,anvendelse for fremstilling av antifedme- og hypokolesterolemiske midler og farmasoytiske sammensetninger som inneholder dem. |
Country Status (25)
Country | Link |
---|---|
US (1) | US7348426B1 (sh) |
EP (1) | EP1175412A1 (sh) |
JP (1) | JP2002543194A (sh) |
KR (1) | KR100610578B1 (sh) |
CN (1) | CN1353699A (sh) |
AU (1) | AU781079B2 (sh) |
BG (1) | BG106146A (sh) |
BR (1) | BR0010139A (sh) |
CA (1) | CA2371757A1 (sh) |
CZ (1) | CZ20013832A3 (sh) |
EE (1) | EE200100540A (sh) |
HR (1) | HRP20010785A2 (sh) |
HU (1) | HUP0600105A3 (sh) |
IL (1) | IL146104A0 (sh) |
MX (1) | MXPA01010916A (sh) |
NO (1) | NO320805B1 (sh) |
NZ (1) | NZ515284A (sh) |
PL (1) | PL351987A1 (sh) |
RU (1) | RU2278114C2 (sh) |
SK (1) | SK15092001A3 (sh) |
TR (1) | TR200103848T2 (sh) |
UA (1) | UA73501C2 (sh) |
WO (1) | WO2000066572A1 (sh) |
YU (1) | YU75101A (sh) |
ZA (1) | ZA200108733B (sh) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002212672A1 (en) * | 2000-10-12 | 2002-04-22 | Dr. Reddy's Research Foundation | Salts of benzothiazine and benzoxazine derivatives and pharmaceutical compositions containing them |
WO2003018553A1 (en) * | 2001-08-29 | 2003-03-06 | Warner-Lambert Company Llc | Oral antidiabetic agents |
WO2003024944A1 (en) * | 2001-09-20 | 2003-03-27 | Dr. Reddy's Laboratories Ltd. | An improved process for the preparation of bicyclic antidiabetic compounds |
WO2003027084A1 (en) * | 2001-09-25 | 2003-04-03 | Dr. Reddy's Laboratories Ltd. | Improved process for the preparation of optically active phenoxazine derivatives as antidiabetic agents |
CN1589258A (zh) * | 2001-10-16 | 2005-03-02 | 雷迪实验室有限公司 | 新的β-苯基-α-氧取代的丙酸衍生物,它的制备方法和它们制备药学上重要的化合物的应用 |
AU2003244514A1 (en) * | 2002-02-07 | 2003-09-02 | Dr. Reddy's Laboratories Limited | Novel polymorphic forms of bicyclic antidiabetic agents: process for their preparation and pharmaceutical compositions containing them |
US6716842B2 (en) | 2002-04-05 | 2004-04-06 | Warner-Lambert Company, Llc | Antidiabetic agents |
KR100841165B1 (ko) * | 2002-04-30 | 2008-06-24 | 유씨비 파마, 에스.에이. | 2,6-퀴놀리닐 및 2,6-나프틸 유도체, 이의 제조 방법 및vla-4 억제제로서의 용도 |
WO2003099800A1 (en) * | 2002-05-23 | 2003-12-04 | Dr. Reddy's Laboratories Limited | An improved process for the preparation of bicyclic antidiabetic agents |
AU2003276234B2 (en) * | 2002-11-08 | 2007-04-19 | F. Hoffmann-La Roche Ag | Substituted 4-alkoxyoxazol derivatives as PPAR agonists |
US7262303B2 (en) | 2003-09-29 | 2007-08-28 | Hoffman-La Roche Inc. | Process for the production of chiral propionic acid derivatives |
DE202004002953U1 (de) * | 2004-02-26 | 2004-04-29 | Winkler, Wilhelm | Verbindungseinheit |
US7572807B2 (en) | 2005-06-09 | 2009-08-11 | Bristol-Myers Squibb Company | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
US7579360B2 (en) | 2005-06-09 | 2009-08-25 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
NZ563739A (en) | 2005-06-09 | 2009-12-24 | Ucb Pharma Sa | 2,6 Quinolinyl derivatives, processes for preparing them and their use as medicament |
US8119658B2 (en) | 2007-10-01 | 2012-02-21 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
RU2684779C2 (ru) * | 2016-02-05 | 2019-04-15 | АО "Институт химических наук им. А.Б. Бектурова" | Применение производного бета-морфолинопропиоамидоксима в качестве противодиабетического средства |
CN110092774B (zh) * | 2018-01-29 | 2022-04-08 | 中国科学院上海药物研究所 | 芳香丙酸类衍生物、及其制备方法和用途 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK173350B1 (da) * | 1985-02-26 | 2000-08-07 | Sankyo Co | Thiazolidinderivater, deres fremstilling og farmaceutisk paæparat indeholdende dem |
GB9027023D0 (en) * | 1990-12-12 | 1991-01-30 | Wellcome Found | Anti-atherosclerotic aryl compounds |
GB9225386D0 (en) | 1992-12-04 | 1993-01-27 | Smithkline Beecham Plc | Novel compounds |
WO1996004261A1 (en) | 1994-07-29 | 1996-02-15 | Smithkline Beecham Plc | Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes |
JPH0912575A (ja) * | 1995-06-28 | 1997-01-14 | Sankyo Co Ltd | ベンゾオキサジンおよびベンゾチアジン誘導体 |
GB9600464D0 (en) * | 1996-01-09 | 1996-03-13 | Smithkline Beecham Plc | Novel method |
AU1856997A (en) * | 1996-02-02 | 1997-08-22 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
GB9604242D0 (en) * | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
GB9606805D0 (en) * | 1996-03-30 | 1996-06-05 | Glaxo Wellcome Inc | Medicaments |
CA2260044A1 (en) | 1996-07-12 | 1998-01-22 | Stephen Alistair Smith | Novel treatment of leptine resistance |
US6265401B1 (en) * | 1997-10-27 | 2001-07-24 | Reddy-Cheminor, Inc. | Bicyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them |
RU2247722C2 (ru) * | 1997-10-27 | 2005-03-10 | Др. Редди`З Лабораториз Лимитед | Производные арилкарбоновых кислот, способы их получения, фармацевтическая композиция на их основе, способы лечения и предупреждения различных заболеваний, промежуточные соединения и способы их получения |
WO1999020614A1 (en) | 1998-05-27 | 1999-04-29 | Dr. Reddy's Research Foundation | Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them |
-
2000
- 2000-04-25 CA CA002371757A patent/CA2371757A1/en not_active Abandoned
- 2000-04-25 SK SK1509-2001A patent/SK15092001A3/sk unknown
- 2000-04-25 WO PCT/IB2000/000501 patent/WO2000066572A1/en not_active Application Discontinuation
- 2000-04-25 KR KR1020017013604A patent/KR100610578B1/ko not_active IP Right Cessation
- 2000-04-25 AU AU39831/00A patent/AU781079B2/en not_active Ceased
- 2000-04-25 RU RU2001132085/04A patent/RU2278114C2/ru not_active IP Right Cessation
- 2000-04-25 MX MXPA01010916A patent/MXPA01010916A/es active IP Right Grant
- 2000-04-25 CZ CZ20013832A patent/CZ20013832A3/cs unknown
- 2000-04-25 HU HU0600105A patent/HUP0600105A3/hu unknown
- 2000-04-25 PL PL00351987A patent/PL351987A1/xx not_active Application Discontinuation
- 2000-04-25 US US09/959,093 patent/US7348426B1/en not_active Expired - Fee Related
- 2000-04-25 JP JP2000615602A patent/JP2002543194A/ja not_active Withdrawn
- 2000-04-25 CN CN00808424A patent/CN1353699A/zh active Pending
- 2000-04-25 UA UA2001118039A patent/UA73501C2/uk unknown
- 2000-04-25 EP EP00919081A patent/EP1175412A1/en not_active Withdrawn
- 2000-04-25 NZ NZ515284A patent/NZ515284A/xx unknown
- 2000-04-25 IL IL14610400A patent/IL146104A0/xx unknown
- 2000-04-25 TR TR2001/03848T patent/TR200103848T2/xx unknown
- 2000-04-25 YU YU75101A patent/YU75101A/sh unknown
- 2000-04-25 EE EEP200100540A patent/EE200100540A/xx unknown
- 2000-04-25 BR BR0010139-7A patent/BR0010139A/pt not_active IP Right Cessation
-
2001
- 2001-10-23 ZA ZA200108733A patent/ZA200108733B/en unknown
- 2001-10-24 HR HR20010785A patent/HRP20010785A2/hr not_active Application Discontinuation
- 2001-10-26 NO NO20015259A patent/NO320805B1/no unknown
- 2001-11-26 BG BG106146A patent/BG106146A/bg unknown
Also Published As
Publication number | Publication date |
---|---|
TR200103848T2 (tr) | 2002-04-22 |
HUP0600105A3 (en) | 2006-11-28 |
KR100610578B1 (ko) | 2006-08-09 |
ZA200108733B (en) | 2003-01-23 |
SK15092001A3 (sk) | 2002-05-09 |
NZ515284A (en) | 2004-12-24 |
JP2002543194A (ja) | 2002-12-17 |
CZ20013832A3 (cs) | 2002-04-17 |
PL351987A1 (en) | 2003-07-14 |
CA2371757A1 (en) | 2000-11-09 |
AU781079B2 (en) | 2005-05-05 |
UA73501C2 (en) | 2005-08-15 |
HUP0600105A2 (en) | 2006-05-29 |
IL146104A0 (en) | 2002-07-25 |
EE200100540A (et) | 2002-12-16 |
NO20015259L (no) | 2001-11-15 |
AU3983100A (en) | 2000-11-17 |
CN1353699A (zh) | 2002-06-12 |
WO2000066572A1 (en) | 2000-11-09 |
YU75101A (sh) | 2005-07-19 |
KR20010113891A (ko) | 2001-12-28 |
MXPA01010916A (es) | 2002-06-21 |
HRP20010785A2 (en) | 2003-02-28 |
EP1175412A1 (en) | 2002-01-30 |
RU2278114C2 (ru) | 2006-06-20 |
BG106146A (bg) | 2002-05-31 |
US7348426B1 (en) | 2008-03-25 |
BR0010139A (pt) | 2004-03-02 |
NO20015259D0 (no) | 2001-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6130214A (en) | Benzothiazin and benzoxazin derivatives; their preparation and uses | |
NO320805B1 (no) | Substituerte bisykliske heterosykler, fremgangsmate for deres fremstilling,anvendelse for fremstilling av antifedme- og hypokolesterolemiske midler og farmasoytiske sammensetninger som inneholder dem. | |
US6440961B1 (en) | Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them | |
EP1082313A1 (en) | Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them | |
RU2235094C2 (ru) | Бета-арил-альфа-оксизамещенные алкилкарбоновые кислоты, способы их получения, промежуточные соединения, способы их получения, фармацевтическая композиция, способы лечения или предупреждения заболеваний на основе новых соединений | |
EP1073643A2 (en) | New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them | |
WO1999019313A1 (en) | Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them | |
US6265401B1 (en) | Bicyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them | |
CA2307068C (en) | Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them | |
MXPA00004032A (en) | Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them | |
CZ20001540A3 (cs) | Bicyklické sloučeniny, způsob jejich přípravy a farmaceutické kompozice s jejich obsahem | |
IL135839A (en) | Bicyclic compounds, processes or the preparation thereof and pharmaceutical compositions containing the same | |
MXPA01008659A (en) | Novel tricyclic compounds and their use in medicine;process for their preparation and pharmaceutical composition containing them | |
WO2003006022A1 (en) | Tetrahydroquinoline derivatives and their use in medicine, process for their preparation and pharmaceutical compositions containing them | |
UA73917C2 (en) | Novel tricyclic compounds and use thereof in the medicine; a method for the preparation thereof and pharmaceutical compositions containing such compounds |